Drugs, Drugs and More Drugs

Clinical advancements in dermatology center on the efficacy and safety of new systemic therapies and the management of complex comorbidities. Duroxolitinib demonstrates significant hair regrowth in alopecia areata, though its use requires careful monitoring for thromboembolic events and mandatory CYP2C9 genotyping. Hidradenitis suppurativa patients frequently present with subclinical spondyloarthritis, necessitating improved screening protocols and potential integration of TNF inhibitors or JAK inhibitors into treatment regimens. While oral minoxidil combined with JAK inhibitors shows promise for alopecia areata, emerging OX40 receptor blockers offer a novel, potentially durable approach for atopic dermatitis. Meanwhile, recent real-world data from Korean populations challenges the established link between hydrochlorothiazide and non-melanoma skin cancer, highlighting the ongoing debate surrounding the clinical significance of this association.